Amnac Opthalmic Suspension

Always wash your hands before using Amnac Opthalmic Suspension. Use only the number of drops that your doctor has prescribed and wait for about five minutes between each drop. If you wear contact lenses, remove them before using the drops and wait for at least 15 minutes before putting them back in. You should not touch the tip of the dropper or bottle. This may lead to infection.

Use of the medicine may cause decreased vision, foreign body sensation in the eyes, increased intraocular pressure, and watery eyes. These are usually temporary and resolve with time. However, if they persist or get worse, you should let your doctor know. Your doctor may be able to suggest ways of preventing or reducing the symptoms.

Before using this medicine, you should tell your doctor about all the other medicines you are taking. You should also tell your doctor if you have any other medical conditions or disorders. Pregnant and breastfeeding women should consult with their doctors before using the medicine.

Post-operative eye pain and inflammation

This medicine is for external use only. Use it in the dose and duration as advised by your doctor. Check the label for directions before use. Hold the dropper close to the eye without touching it. Gently squeeze the dropper and place the medicine inside the lower eyelid. Wipe off the extra liquid.

Amnac Opthalmic Suspension is a non-steroidal anti-inflammatory drugs (NSAID) which works by blocking the release of certain chemical messengers that cause pain and inflammation (redness and swelling) in the eye.

Information not available at the moment. Please check back later.

Your doctor has prescribed Amnac Opthalmic Suspension for the relief of post-operative eye pain and inflammation (redness and swelling).

Apply pressure on the corner of the eye (close to the nose) for about 1 minute, immediately after instilling the drop.

Usually, a 4 to 6-week course may be necessary.

Wait for at least 5-10 minutes before delivering the next medication in the same eye to avoid dilution.

Stinging sensation may occur for 1-2 mins. Notify your doctor if it persists for longer.

Notify your doctor if you are on blood thinners or have bleeding problems.

Use the eye drops within 4 weeks of opening the bottle.

Information not available at the moment. Please check back later.

In Post-operative eye pain and inflammation

Amnac Opthalmic Suspension helps relieve symptoms such as pain, redness, swelling, itching and watering of eyes after an operation of the eyes. This medicine works by decreasing the production of certain chemicals that cause inflammation of the eyes. This will make it easier for you to go about your daily activities. Use it as prescribed to get the most benefit. If you see no improvement even after a week, talk to your doctor.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Watery eyes

Increased intraocular pressure

Foreign body sensation in eyes

Decreased vision

Alcohol:

No interaction found/established

Pregnancy:CONSULT YOUR DOCTOR

Amnac Opthalmic Suspension may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

Breast feeding:CONSULT YOUR DOCTOR

Information regarding the use of Amnac Opthalmic Suspension during breastfeeding is not available. Please consult your doctor.

Driving:UNSAFE

Amnac Opthalmic Suspension may cause blurring of your vision for a short time just after its use. Do not drive until your vision is clear.

Kidney:

No interaction found/established

Liver:

No interaction found/established

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 970.

Nepafenac. Fort Worth, Texas: ALCON LABORATORIES, INC.; 2005 . view

Central Drugs Standard Control Organisation . view